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Introduction
Androgens play a key role in the control of spermatogenesis but 
the mechanisms underlying their effects remain poorly under-
stood.1-4 Various strategies have been used to identify the steps in 
germ cell development that depend most on androgens. The most 
classical approach has been to study the effects of a drastic reduc-
tion in the intratesticular concentration of testosterone as well 
as the result of subsequent treatment by exogenous androgens. 
Drastic decreases in intratesticular testosterone (or testosterone 
action) were obtained by a variety of techniques including: sur-
gical or chemical hypophysectomy, administration of exogenous 
androgens and/or estrogens, administration of anti-androgens, 
A mouse model with a Sertoli cell (SC)-selective ablation of the androgen receptor (Ar)—the SCArKO mouse—
demonstrated that the effects of androgens on spermatogenesis depend on the presence of an active Ar in SC. this 
model has been extremely valuable in the study of the effects of androgens on the initiation of spermatogenesis. 
However, due to the early (prenatal) inactivation of the Ar SCArKO mice develop a complete block in meiosis, making 
it impossible to study the effects of androgens on postmeiotic steps of germ cell development. It would therefore be 
of interest to develop a model in which the Ar can be ablated at any chosen time point. Here we used a mouse line 
ubiquitously expressing a tamoxifen (tM)-inducible Cre recombinase to develop an inducible Ar knockout model (iArKO). 
It is shown that treatment with tM (3 mg/day) for five consecutive days efficiently inactivates the Ar in testicular tissue 
and decreases the expression of known Ar-target genes in SC (Rhox5, Spinlw1) without markedly affecting testicular cell 
composition one day after the final injection. tM treatment did, however, decrease serum gonadotropin levels and the 
expression of several Leydig cell genes (StAR, Cyp17a1, Insl3), resulting in decreased testosterone levels. Nevertheless, the 
intratesticular testosterone concentration still far exceeds the estimated concentrations required to saturate the Ar. It 
may be concluded that the study of androgen-responsive postmeiotic genes in SC may be feasible using a tM-inducible 
Ar knockout model provided that appropriate controls are included correcting for off-target effects of tM.
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immunoneutralization of LH and administration of the Leydig 
cell (LC) toxicant ethane dimethane sulphonate (EDS).2 These 
approaches have greatly contributed to our understanding of the 
specific role of androgens in the control of spermatogenesis but 
they show a number of inherent limitations. First, all these tech-
niques reduce the intratesticular level of testosterone to only a few 
percent of the control value.5 Given the high intratesticular level 
of testosterone under control conditions, however, some residual 
androgen action cannot be excluded. Second, it may take a con-
siderable amount of time before a maximal reduction in intrates-
ticular testosterone is observed. Third, none of these techniques 
offers any information on the exact target cell(s) responsible for 
the observed effects of androgens. More recently, genetic models 
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Results
TM treatment reduces accessory sex organ weight and AR 
expression in iARKO mice. To distinguish between effects due 
to TM-induced AR ablation and effects directly related to TM 
itself, both ARflox/y mice ubiquitously expressing a TM-inducible 
Cre recombinase (iARKO) and control mice carrying a mutated 
AR with a floxed exon 2 were treated with either TM or vehicle 
(Fig. 1). Routinely TM treatment (3 mg/day intraperitoneally 
for five consecutive days) was initiated on day 50 and animals 
were killed on day 55. In some experiments mice received a lower 
dose of TM (1 mg/day) or were killed on later time points (day 
61 or 104).
As shown in Figure 2A TM treatment (3 mg/day) does not 
affect body weight of control or iARKO animals as measured 
on day 55. It may be noted that control and iARKO mice also 
have identical body weights in the pretreatment period except on 
day 35 where—for unknown reasons—iARKO animals display 
a slight decrease in body weight. Figure 2B shows that under the 
same conditions TM treatment does not affect the weight of any 
of the studied androgen target organs (kidney, testis, epididy-
mis, seminal vesicles, anterior prostate and ventral prostate) in 
control mice whereas in iARKO mice significant reductions in 
weight are observed for the epididymis, the seminal vesicles and 
the anterior prostate. At later time points after administration 
of TM (3 mg/day) the decrease in epididymis, seminal vesicle 
and anterior prostate weight in iARKO mice becomes more pro-
nounced and a significant reduction in weight is also observed for 
testis, ventral prostate and kidney (Table 1). A similar decrease 
in androgen target organ weight is not observed in control mice 
(except for epididymis at day 61 and prostate at day 104) (Table 
2). Comparable but somewhat less pronounced selective effects 
on target organ weight in iARKO animals are observed at day 
55 after treatment with TM 1 mg/day (compare Tables 1 and 
2). The observed effects on target organ weight are compatible 
with the hypothesis that TM selectively induces AR ablation in 
iARKO animals.
To examine whether TM treatment in fact results in AR inac-
tivation (by excision of exon 2) in iARKO mice genomic DNA 
was prepared from a variety of tissues (tail tip, testis, epididymis, 
kidney and brain). PCR analysis (Fig. 3) confirms that no exci-
sion of exon 2 takes place in control mice treated with vehicle or 
TM or in iARKO mice treated with vehicle. In iARKO mice 
treated with TM, however, a smaller (404 bp) PCR fragment, 
representative for the inactivated AR, is observed. A very weak 
band corresponding to the PCR fragment of the intact floxed 
AR (952 bp) is also seen in all the organs studied suggesting that 
excision of exon 2 is not 100% efficient.
TM treatment diminishes AR expression in iARKO mice 
testes. To evaluate more quantitatively the effect of TM admin-
istration on testicular AR expression in iARKO and control 
mice, transcript levels were measured by a qPCR assay specifi-
cally designed to detect only AR with an intact exon 2. As shown 
in Figure 4 TM (3 mg/day for five days) does not reduce AR 
transcript levels (as measured on day 55) in control mice. In the 
testes of iARKO mice, however, transcript levels are reduced to 
including mice with an inherent defect in the production of 
gonadotropins (hpg mice) and transgenic mice with a defect in 
the LH receptor (LuRKO) have been used to study the effects 
of exogenous androgens on germ cell development.6-8 Also in 
these models however, identification of the testicular target cells 
responsible for the observed effects remains impossible.
The development of the conditional knockout technology has 
opened novel perspectives for the study of androgen action in the 
testis and has created the possibility to avoid or reduce some of 
the limitations imposed by previous approaches. Various mouse 
models have now been developed in which the AR gene has been 
selectively inactivated in distinct testicular target cells. The main 
conclusion from these models is that the Sertoli cell (SC) plays 
a central role in the effects of androgens on spermatogenesis9-12 
although androgen action on peritubular myoid cells (PTMs) is 
also essential to support SC development and function.13 Most of 
the available models of SC-selective AR inactivation (SCARKO 
models) have used a Cre (Cyclization recombination) recombi-
nase driven by the Anti-Müllerian Hormone (AMH) promoter 
to inactivate the AR gene.9-12 In these models the AR gene in SCs 
is inactivated around day 15 of embryonic development, more 
than a week before the encoded AR protein becomes normally 
expressed in these cells. These SCARKO mice typically develop 
a block in meiosis,9,10,12 supporting the contention that meiotic 
progression is one of the most important steps controlled by 
androgens. However, from the experimental approaches men-
tioned in the previous paragraph and a model with a less com-
plete knockout of the AR in SC which also suffers from a general 
decrease in AR expression,11 it is known that androgens also have 
effects on postmeiotic events in the spermatogenic cascade: they 
are essential for adhesion of round and elongated spermatids to 
SCs14-18 and they also play a crucial role in the control of spermia-
tion.4,16,17,19-21 Given the complete block at the level of meiosis in 
SCARKO mice, the cellular and molecular mediators of the lat-
ter processes cannot be studied in the SCARKO model. In order 
to overcome this limitation it would be of interest to develop an 
inducible SCARKO (iSCARKO) model in which the expression 
of the Cre recombinase is controlled not only in space but also in 
time. This could be done, for instance, by placing the Cre recom-
binase under the control of a promoter that drives Cre expression 
in adult SCs and by replacing the classical Cre recombinase by 
an inducible variant. Tamoxifen (TM)-inducible Cre recombi-
nases (produced by fusing the native Cre to a modified estro-
gen receptor ligand binding domain that selectively recognizes 
TM and its active metabolite 4-hydroxy(OH)-TM) have been 
described in reference 22. Since mice expressing a TM-inducible 
Cre selectively in SC are not yet available, we explored the feasi-
bility of this type of approach by generating an inducible global 
AR knockout model (iARKO). iARKO mice were produced by 
crossing a commercially available mouse strain that ubiquitously 
expresses a TM-inducible Cre recombinase (Cre-ERTM) 23 with 
a mouse strain carrying a floxed exon 2 of the AR (ARflox mice) 
generated in our laboratory. Special attention was given to the 
extent and time course of TM-induced AR inactivation in the 
testis and to potential off-target effects of TM treatment on tes-
ticular function.
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seen in any of the treatment groups as evaluated by H&E stain-
ing on day 55 (data not shown). The latter observation is in line 
with the lack of effect on tubular diameter one day after final 
treatment (Tables 1 and 2). Seven and 50 d after treatment, how-
ever, impaired spermatogenesis was evident (compare Figs. 5D 
and 6D) as would be expected by lack of androgen signaling. 
This was further confirmed by a decrease in tubular diameters in 
iARKO mice treated with TM (Table 1).
Effects of TM treatment and AR ablation on Sertoli and 
Leydig cell function. To study the effect of TM treatment and 
AR ablation on the expression of androgen-regulated genes in SC, 
we compared the effect of TM on the expression of Rhox5 and 
Spinlw1 in iARKO and control mice. Both Rhox5 and Spinlw1 
have previously been shown to be under the direct control of 
the AR in SC.24-26 As shown in Figure 4 TM treatment does 
14% of the vehicle treated control. Table 1 shows that in iARKO 
mice treated with 3 mg TM/day there is a further decrease in AR 
transcript levels (down to 4%) at day 61 and day 104. Moreover, 
a dose of 1 mg TM is considerably less effective (measured on day 
55 only). Under none of the conditions studied TM affects AR 
transcript levels in control mice (Table 2).
Immunohistochemical evaluation of AR protein expression 
immediately after (day 55), one week after (day 61) and 50 d 
after TM treatment reveals that AR expression is comparable in 
the testes of control mice treated with vehicle or TM and iARKO 
mice treated with vehicle (Figs. 5 and 6A–C). AR expression 
in TM-treated iARKO mice, however, is clearly diminished: 
staining is virtually absent in LC and PTM. Weak AR staining 
may be noted in some SC (Figs. 5D and 6D, white arrowheads). 
Interestingly, no noticeable effects on testicular morphology are 
Figure 1. Generation of iArKO mice and the tamoxifen (tM) induction protocol. (A) Mice with a ubiquitous knockout of the Ar (iArKO) were gener-
ated by crossing female mice homozygous for a floxed Ar allele (ARflox/flox) with male mice carrying a tM-inducible Cre recombinase (heterozygous; 
CAGGCreertM+/-) as described in the Material and Methods section. As a result of this breeding scheme 50% of the male progeny carried the floxed Ar 
allele as well as the ubiquitously expressed tM-inducible Cre recombinase (Arflox/y;CAGGCreertM+/-: further referred to as iArKO mice) and 50% of the 
male progeny carried only the floxed Ar allele (Arflox/y;CAGGCreertM-/-: further referred to as control). Both control and iArKO mice were divided in a 
tM-treated (orange) and a control-treated (green) group. Knockout of the Ar occurs only in tM-treated animals carrying a floxed Ar allele and the 
tM-inducible Cre recombinase (Ar-/y; CAGGCreertM+/-; boxed mouse). Other treatment groups were included as a vehicle control, as a control for the 
effects of tM or as a control for the leakiness of the system (as indicated under each mouse). to derive a SC-specific knockout the promoter driving Cre 
expression has to be replaced by a promoter expressed specifically in adult SC. (B) A scheme of the tM induction protocol. From day 50 on male mice 
(iArKO and control) were injected intraperitoneally with tM (1 mg or 3 mg) or vehicle for five consecutive days. Animals were sacrificed and organs 
were collected one, seven or 50 d after the final treatment (day 55, 61 and 104 respectively).
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The effect of TM treatment and AR ablation on LC func-
tion was evaluated by measuring the transcript levels of three LC 
genes: StAR, Cyp 17a1 and Insl 3. In control mice TM treatment 
significantly reduces the expression of the studied genes under 
nearly all the conditions examined indicating that TM affects LC 
function via mechanisms that do not depend on AR inactivation 
(Fig. 4 and Table 2). In iARKO mice TM treatment also reduces 
the expression of Cyp17a1 and Insl3. The TM effect on StAR 
not decrease the transcript levels of the studied genes in control 
mice on day 55 whereas in iARKO mice expression of Rhox5 and 
Spinlw1 is reduced to 51% and 66% of the vehicle treated iARKO 
mice respectively. In iARKO mice further decreases in Rhox5 and 
Spinlw1 expression may be noted on day 61 and 104 (Table 1). 
The 1 mg TM dose is clearly less effective. In control mice TM has 
no effects on Rhox5 expression under any of the conditions studied 
and increases rather than decreases Spinlw1 expression (Table 2).
Figure 2. Body and tissue weights of iArKO and control mice treated with vehicle (V) or tamoxifen (tM). (A) Body weights (mean ± SeM) of iArKO and 
control mice (Arflox/y) were measured before treatment (day 35, 42 and 49) and one day after treatment (day 55) with V or tM (3 mg/day for five con-
secutive days). (B) tissue weights (mean + SeM) for kidney (K), testis (t), epididymis (e), seminal vesicle (SV), anterior prostate (Ap) and ventral prostate 
(Vp) measured one day after treatment (day 55). Control + V: control mice treated with vehicle (n = 7); control + tM: control mice treated with tM (n = 
8); iArKO+V: iArKO mice treated with vehicle (n = 5); iArKO+tM: iArKO mice treated with tM (n = 5). ANOVA supplemented with a Fisher LSD test was 
used to compare body and tissue weights of different treatment groups. Values that differ significantly (p ≤ 0.05) are indicated by different lowercase 
letters (a–c).
Table 1. effect of tamoxifen (tM) treatment on tissue weights, testicular transcript levels and serum hormone levels in iArKO animals
dosage TM/day 1 mg 3 mg 3 mg 3 mg
sacrifice on day day 55 day 55 day 61 day 104
tissue weights
kidney 95.9 ± 4.4 93.2 ± 1.9 83.2 ± 2.9* 77.2 ± 6.2
testis 98.6 ± 5.5 95.9 ± 3.7 84.4 ± 5.0* 31.9 ± 3.1*
epididymis 80.5  ± 3.5* 67.9 ± 3.6* 42.7 ± 2.8* 35.1 ± 2.5*
seminal vesicle 54.1 ± 5.4* 52.0 ± 6.2* 13.2 ± 1.5* 9.1 ± 1.4*
anterior prostate 65.3 ± 7.1* 58.7 ± 7.3* 37.7 ± 7.4* 20.7 ± 3.9*
ventral prostate 82.4 ± 9.2 69.4 ± 19.8 52.9 ± 9.9* 30.8 ± 6.5*
q-RT-PCR on testis extracts
AR 42.6 ± 5.9* 13.7 ± 2.2* 4.3 ± 1.2* 3.7 ± 1.4*
Rhox5 78.4 ± 6.3* 51.1 ± 5.1* 12.7 ± 1.6* 4.8 ± 1.5*
Spinlw1 112.2 ± 19.4 65.5 ± 4.9* 40.4 ± 7.7* 9.0 ± 2.9*
StAR 72.3 ± 10.1 117.1 ± 9.9* 38.5 ± 6.0* 137.2 ± 22.2
Cyp17a1 68.8 ± 9.5 68.7 ± 6.0* 54.3 ± 9.2* 69.7 ± 3.0*
Insl3 44.6 ± 8.6* 54.1 ± 6.8 5.1 ± 1.3* 1.2 ± 0.2*
serum level
FSH ND 63.2 ± 5.5* ND 65.0 ± 12.9
LH ND 128.6 ± 32.5 ND 434.5 ± 63.0*
Basal testosterone ND 57.3 ±  24.3 ND 41.6 ± 8.7
tubular diameter   ND 94.9 ± 1.6 85.4 ± 1.3* 68.5 ± 1.7*
iArKO mice were treated with vehicle (V) or tamoxifen (tM; 1 or 3 mg/day) from day 50 on for five consecutive days. tissue weights, testicular transcript 
levels (measured by qpCr) and serum hormone levels were measured one day after treatment (day 55), seven days after treatment (day 61) and 50 days 
after treatment (day 104). the data shown (mean ± SeM) represent values in iArKO mice treated with tM expressed relative to values observed in 
iArKO mice treated with V (arbitrarily assigned a value of 100). Statistical analysis was performed by ANOVA supplemented with a Fisher LSD test. 
Values that differ significantly (p ≤ 0.05) are indicated by an asterisk. ND = not determined.
www.landesbioscience.com Spermatogenesis 345
Discussion
The data presented show that, in the currently developed iARKO 
model, intraperitoneal treatment with TM (3 mg/day for five 
consecutive days) successfully inactivates the AR in all target tis-
sues studied including the testis. One day after the final injection 
the concentration of AR transcripts in the testis, the main focus 
of our research, was reduced to 14% of the control. This reduc-
tion was accompanied by a significant decline in the mRNA 
concentrations of Rhox5 and Spinlw1 (to 51% and 66% of the 
control respectively), two SC genes that are directly controlled 
by the AR via androgen responsive elements (ARE) located in 
their promoter regions.24-26 Interestingly, at this early time point 
TM treatment did not affect testicular cell composition, a fea-
ture that may considerably facilitate future studies on changes in 
gene expression caused by AR inactivation. Moreover, identical 
treatment of control mice that do not carry the TM-inducible 
Cre recombinase did not show changes in the expression levels 
of Rhox5 and Spinlw1, indicating that the observed effects in 
iARKO animals (that carry the TM-inducible Cre) are caused 
by AR inactivation and not by any other direct or indirect effect 
of TM. Fifty days after treatment AR, Rhox5 and Spinlw1 tran-
script levels are further decreased and tubular diameter in TM 
treated iARKO mice is reduced to 68% of that observed in vehi-
cle treated controls (Table 1). At this time point sperm produc-
tion (as measured by histological evaluation of testicular sections 
and epididymal sperm counts) is virtually absent (Fig. 6D and 
Day 104; data not shown). In TM treated control mice none of 
the mentioned transcript levels is decreased and only a limited 
expression, however, seems to be neutralized by TM-induced AR 
inactivation (particularly at day 55 and 104) a finding that is 
compatible with the well-known inhibitory effects of androgens 
on StAR expression.27
Effects of TM treatment on the endocrine system. To fur-
ther evaluate the effects of TM on endocrine function and par-
ticularly on androgen production, gonadotropin levels, serum 
testosterone levels and intratesticular testosterone levels were 
determined in vehicle and TM-treated control and iARKO 
mice. The data observed on day 55 are summarized in Figure 
5. TM reduces FSH levels to a similar degree (by approxi-
mately 30%) in control and iARKO mice (Fig. 7A). LH lev-
els (Fig. 7B) are significantly lowered (by approximately 60%) 
in TM-treated control mice but are unaffected in TM-treated 
iARKO mice, conceivably by reduced hypophyseo-hypotha-
lamic feedback. In control mice serum and intratesticular 
testosterone levels (Fig. 7C and D respectively) are markedly 
reduced upon treatment with TM. In TM-treated iARKO mice 
a tendency to lower serum and intratesticular testosterone levels 
may also be noted, but—given the wide variation between indi-
vidual animals—the difference is not statistically significant. 
Nonetheless, testosterone measurements after stimulation with 
human Chorionic Gonadotropin (hCG; Fig. 7E and F) indicate 
that the capacity of LC to produce androgens is impaired both 
in control and in iARKO mice treated with TM. Fifty days 
after TM treatment (day 104) LH levels tend to be increased 
in control mice (Table 2). A more pronounced and significant 
increase is observed in iARKO animals (Table 1).
Table 2. effect of tamoxifen (tM) treatment on tissue weights, testicular transcript levels and serum hormone levels in Arflox/y control animals
dosage TM / day 1 mg 3 mg 3 mg 3 mg
sacrifice on day day 55 day 55 day 61 day 104
tissue weights
kidney 105.2 ± 4.9 99.2 ± 3.1 94.9 ± 4.8 117.1 ± 13.1
testis 104.9 ± 3.3 95.7 ± 2.9 102.8 ± 1.6 94.1 ± 6.6
epididymis 104.9 ± 4.5 90.8 ± 4.5 83.2 ± 5.8* 95.3 ± 4.0
seminal vesicle 108.0 ± 8.0 118.6 ± 5.9 82.6 ± 12.2 89.6 ± 3.4
anterior prostate 109.4 ± 7.7 105.2 ± 7.6 105.9 ± 16.6 73.9 ± 7.8
ventral prostate 95.2 ± 10.7 114.0 ± 12.7 104.3 ± 7.3 60.6 ± 5.0*
q-RT-PCR on testis extracts
AR 82.6 ± 8.5 112.3 ± 7.8 82.4 ± 15.2 111.4 ± 21.8
Rhox5 103.6 ± 11.6 109.0 ± 6.1 108.2 ± 20.1 111.5 ± 9.4
Spinlw1 137.4 ± 18.2 115.9 ± 6.1* 91.3 ± 11.0 138.0 ± 11.0*
StAR 14.1 ± 1.7* 26.7 ± 3.7* 7.5 ± 0.9* 82.9 ± 8.7
Cyp17a1 59.0 ± 8.7* 70.9 ± 4.9* 59.4 ± 4.1* 99.2 ± 10.0
Insl3 65.8 ± 8.8 58.9 ± 5.3* 11.9 ± 2.0* 29.4 ± 5.9*
serum level
FSH ND 76.7 ± 4.1* ND 96.7 ± 15.0
LH ND 35.4 ± 3.4* ND 242.6  ± 74.8
Basal testosterone ND 11.3 ± 6.6* ND 25.4 ± 10.4
tubular diameter   ND 104.3 ± 2.0 101.3 ± 3.9 95.4 ± 1.2*
Arflox/y control mice were treated with vehicle (V) or tamoxifen (tM; 1 or 3 mg/day) from day 50 on for five consecutive days. tissue weights, testicular 
transcript levels (measured by qpCr) and serum hormone levels were measured one day after treatment (day 55), seven days after treatment (day 61) 
and 50 days after treatment (day 104). the data shown (mean ± SeM) represent values in Arflox/y mice treated with tM expressed relative to values ob-
served in Arflox/y mice treated with V (arbitrarily assigned a value of 100). Statistical analysis was performed by ANOVA supplemented with a Fisher LSD 
test. Values that differ significantly (p ≤ 0.05) are indicated by an asterisk. ND = not determined.
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regulated indirectly via androgen-dependent processes 
such as the presence of particular stages of developing 
germ cells. Moreover, immunohistochemical studies 
both after treatment with a 1 mg dose of TM (data not 
shown) and a 3 mg dose of TM (Figs. 5 and 6) suggest 
that AR inactivation in SCs may be slower or less effi-
cient than in other testicular cells. In fact, one day after 
treatment the AR is undetectable in LCs, interstitial 
cells and PTMs whereas some SCs still stain positive. 
Whether this less efficient AR inactivation in SCs is 
due to a lower expression of the Cre transgene in SCs or 
to a less efficient penetration of TM in SCs, conceivably 
due to the expression of drug transporters involved in 
the protective function of SCs during germ cell devel-
opment,28,29 remains to be investigated.
Estrogens are known to affect testicular function 
by a variety of pathways.30,31 Accordingly, when high 
doses of TM are used to activate the inducible Cre in 
iARKO mice, the possibility should be considered that 
some of the observed effects are not due to AR inacti-
vation but to confounding (off-target) effects of TM. 
TM is a non-steroidal anti-estrogen commonly used 
for the treatment of hormone-dependent early breast 
cancer in pre-menopausal women.32 Depending on 
the concentration used, and the target organ studied, 
however, its action may range from that of a pure estro-
gen antagonist to that of an estrogen agonist.32 In the 
present study there are obvious effects of TM treatment 
on the endocrine system. In control animals treated 
with TM, FSH and LH concentrations in serum, one 
day after treatment, are diminished by 23% and 65% 
respectively indicating that TM acts as an ER agonist 
at the pituitary-hypothalamic level.33 Interestingly, in 
identically treated iARKO mice the effect of TM on 
LH concentration is neutralized, most likely by inacti-
vation of the AR in the central feedback system and by 
the subsequent elimination of the suppressive effects of 
androgens on LH secretion. Furthermore, TM treat-
ment of control mice markedly reduces serum as well as intrates-
ticular levels of testosterone. The observation that this reduction 
is (partially) reversed in iARKO mice suggests that this effect 
may be related at least in part to the effects of TM on LH. This 
is obviously not the only explanation, however. In fact, stimu-
lation with hCG reveals that treatment with TM decreases the 
capacity of LCs to produce testosterone. This decrease is at least 
as severe in iARKO animals as in control mice. LCs are known 
to express the estrogen receptor (ER; both ERα and ERβ) 34,35 
and estrogens have been proven to be important regulators 
of LC steroidogenesis and proliferation.36-39 Studies in ERα 
knockout mice indicate that the effects of estrogens (or estro-
genic endocrine disruptors) on LC function are mainly medi-
ated through the ERα.37,40,41 To evaluate potential direct effects 
of TM on LC function we measured transcript levels of three 
genes known to be downregulated by estrogens: StAR (encoding 
a protein involved in the mitochondrial transport of cholesterol, 
a rate-limiting step in steroidogenesis42), Cyp17a1 (encoding the 
(5%; not statistically significant) decrease in tubular diameter is 
observed.
Inactivation of the testicular AR via activation of the 
TM-inducible Cre requires a high dose of TM. Administration 
of a 1 mg dose of TM had only limited effects on AR and Rhox5 
expression (a decrease to 43% and 78% respectively) and did not 
affect Spinlw1 transcript levels. Moreover, even at the 3 mg/day 
dose of TM AR inactivation occurred more slowly than antici-
pated. AR mRNA concentration was decreased to 14% of the 
control one day after the final injection and decreased further 
down to 4% on day 7 and 50 after treatment. Even slower declines 
were observed for the expression of the androgen-controlled SC 
genes Rhox5 and Spinlw1 (down to 5% and 9% respectively 50 d 
after treatment). The slow decline in these SC genes controlled 
by androgens probably reflects that low levels of AR may still be 
able to maintain relatively high levels of expression. Alternatively, 
it may be speculated that the expression of these genes does not 
depend exclusively on direct effects of androgens but is also 
Figure 3. the effect of tamoxifen (tM) and vehicle (V) treatment on Ar inactivation 
in control and iArKO mice. Control (Arflox/y) or iArKO mice were treated with V or 
tM (3 mg/day) as indicated. excision of the floxed exon 2 of the Ar was monitored 
by pCr on genomic DNA obtained from a tail tip before treatment (lane 2) and 
genomic DNA obtained from a tail tip (lane 3), testis (lane 4), epididymis (lane 5), 
kidney (lane 6) and brain (lane 7) one day after treatment (day 55). Lane 1 shows a 
trackIttM 100 bp DNA ladder (Invitrogen). Lane 8 shows a negative control sample 
without genomic DNA. the 952 bp fragment (black arrowhead) corresponds to the 
intact floxed Ar allele. excision of the floxed exon 2 results in a 404 bp fragment 
(white arrowhead). excision is only observed in iArKO mice treated with tM (D: 
lane 3–7). (A–D) Data derived from one representative animal from the indicated 
genotype.
www.landesbioscience.com Spermatogenesis 347
CMV promoter fused to seven Tet-operator (tetO) sequences 
and (3) the ARflox mouse line. The mating scheme of these cell-
specific tetracycline-inducible knockout mice is therefore more 
complicated and increases animal housing costs considerably. 
Moreover, also in this system, off-target effects of the inducer, 
doxycycline, will have to be considered. Doxycycline is an anti-
biotic that can inhibit protein synthesis48 and that acts as an 
inhibitor of matrix metalloproteinases, which are known to be 
essential in the dynamic regulation of the SC barrier.49 Moreover, 
experience with doxycycline-inducible systems in our laboratory 
indicates that these systems often display relatively high levels of 
basal (uninduced) activity. Another option might be the use of an 
interferon-inducible Cre recombinase. In this system Cre is con-
trolled by a promoter that is strongly activated by the administra-
tion of interferon-α or -β.50 Again off-target effects of interferon 
treatment should be carefully considered. In fact, interferon is 
not only an important cytokine in the control of the immune 
system but also a paracrine regulator of normal testicular func-
tion with effects on both germ cell development and steroidogen-
esis.51,52 Moreover, endogenous interferon has been reported to 
induce leaky Cre expression in absence of the inducer.50
It may be concluded that TM treatment in iARKO mice 
largely inactivates AR expression in testicular cells and signifi-
cantly affects transcript levels of androgen-regulated genes in 
SCs as well as in LCs. Immediately after the five-day TM treat-
ment period testicular cell composition is not noticeable affected, 
making the iARKO a promising experimental tool to identify 
androgen-regulated genes in testicular target cells. High doses 
of TM are needed to obtain efficient AR ablation in the testis 
and these doses have effects on the testis that are not directly 
17α-hydroxylase/17,20-lyase, a key enzyme in the steroidogenic 
pathway) and Insl3 (a regulator of testicular descent and a marker 
of differentiated LCs43). Expression of all three marker genes was 
decreased in testes of TM-treated control animals immediately 
after treatment confirming earlier in vitro and in vivo studies 
showing that TM acts as an ER agonist in LCs.33,44 In iARKO 
animals the inhibitory effect of TM on StAR expression was com-
pletely abolished, an observation compatible with TM-induced 
AR inactivation in LCs and with the known inhibitory effects 
of androgens on StAR expression.27 Despite these inhibitory 
effects of TM on LC steroidogenesis it should be stressed that 
the decrease in intratesticular testosterone remains relatively mild 
in control animals and even non-significant in iARKO mice. 
Residual levels still exceed 10 nM, a concentration that should be 
sufficient to saturate the AR2,45,46 as also reflected by the lack of 
effect of TM on the expression of Rhox5 and Spinlw1 in control 
animals. An important implication is that the effects observed on 
SC gene expression are the result of AR inactivation and not of 
diminished testosterone concentrations in the testis.
The use of other inducible knockout strategies (not depen-
dent on TM administration) was certainly contemplated. One 
option is the combined application of a tetracycline-controlled 
transactivator and Cre/loxP technology. For the development 
of a time-controlled cell-specific knockout of the AR the “Tet-
On”-system, which will switch on gene expression when tetracy-
cline/doxycycline is administered, could be used.47 This system 
relies on the existence/generation of three distinct mouse lines: 
(1) a mouse line that expresses a mutant/reverse tetracycline-
controlled transactivator (rtTA) in a cell-specific manner, (2) 
a mouse line expressing Cre under the control of the minimal 
Figure 4. transcript levels for the Ar and representative SC and LC genes in testes of iArKO and control mice treated with vehicle (V) or tamoxifen 
(tM). testicular transcript levels for AR, Rhox5, Spinlw1, StAR, Cyp17a1 and Insl3 in iArKO and control mice treated with V or tM (3 mg/day for five con-
secutive days) were measured by qpCr on day 55. Measurements were corrected for exogenously added luciferase mrNA as described in the Methods 
section. Values are expressed relative to the mean transcript level of iArKO mice treated with V (arbitrarily assigned a value of 100). Data represent the 
mean ± SeM of 5–7 independent measurements. Statistical analysis was performed as described in Figure 2. Values that differ significantly (p ≤ 0.05) 
are indicated by different lowercase letters (a–c).
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Materials and Methods
Ethics statement. All animals were treated according to the 
National Institutes of Health Guide for the Care and Use of 
Laboratory Animals, and all experiments were approved by the 
“Ethical Committee Animal Tests” of the Catholic University of 
Leuven.
Generation of transgenic mice. Mice with an inducible ubiq-
uitous knockout of the AR (iARKO) were generated by crossing 
female mice (98% CD1) homozygous for a floxed AR allele (ARflox/
flox) 9 with male mice (B6.Cg-Tg(CAG-cre/Esr1)5Amc/J from 
The Jackson Laboratory) carrying a tamoxifen (TM)-inducible 
Cre recombinase. The expression of this Cre is controlled 
by a chimeric promoter of the cytomegalovirus immediate-
early enhancer and the chicken β-actin promoter/enhancer 
(CAGGCreERTM).23 As a result of this breeding scheme 50% 
of the male progeny carried the floxed AR allele as well as the 
ubiquitously expressed TM-inducible Cre recombinase (ARflox/y; 
CAGGCreERTM+/-: further referred to as iARKO mice) and 
50% of the male progeny carried only the floxed AR allele 
related to the ability of TM to induce Cre activation and AR 
ablation. These effects can largely be accounted for, however, by 
including control animals receiving identical TM treatment. The 
TM-induced decrease in testosterone production and FSH con-
centration observed in the present experiments, for instance, is 
not important enough to confound interpretation of the results. 
Even if this would turn out to be a problem under certain con-
ditions, the effects can probably be neutralized by exogenous 
administration of testosterone and/or FSH. The iARKO model 
has the advantage that AR inactivation can be induced at a cho-
sen time point, an interesting feature that is lacking in SCARKO 
mice and that precludes studies on postmeiotic effects of andro-
gens on germ cell development in the latter model. The disad-
vantage of the iARKO is that AR ablation is not cell-specific. 
The data shown here, however, prove that it should be feasible 
and worthwhile to develop an iSCARKO model in which the 
TM-inducible Cre recombinase is placed under the control of a 
SC-selective promoter making Cre expression controllable both 
in space and in time. Attempts to develop such an iSCARKO 
model are underway.
Figure 5. Immunohistochemical study of Ar expression in testes of iArKO and control mice treated with vehicle (V) or tamoxifen (tM) and evaluated 
one day after treatment. Ar expression was evaluated on day 55 in testes of iArKO and control mice treated with V or tM (3 mg/day for five consecu-
tive days). At least five animals were studied for each experimental group. the intensity of Ar staining was comparable in control mice treated with V 
or tM (A and B respectively) and iArKO animals treated with V (C). Ar staining was markedly diminished, however, in iArKO mice treated with tM (D). 
In the latter animals virtually no Ar staining was observed in LCs, ptMs and testicular arterioles. Weak Ar staining could be detected in a number of 
SCs (white arrowheads) whereas others were negative (black arrowheads). Scale bar = 100 μm.
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(ARflox/y;CAGGCreERTM-/-: further 
referred to as control) (Fig. 1A).
Handling of mice and induction of 
AR knockout by treatment with TM. 
Routinely TM (T5648, Sigma-Aldrich) 
was dissolved in ethanol (150 mg/ml), 
by sonication (5 min) and warming up to 
40°C. The ethanol solution was diluted 
1/10 in arachis oil (Fagron) to a final con-
centration of 15 mg TM/ml.22 To induce 
AR knockout, iARKO and control mice 
were injected intraperitoneally with TM 
(1 mg or 3 mg) or with vehicle (ethanol 
in arachis oil: 1/10) for five consecutive 
days starting from day 50 (Fig. 1B). TM- 
and vehicle-treated animals were housed 
in separate cages.
Mice were weighed before treatment 
(on day 35, 42 and 49), one day after the 
final injection (day 55) and thereafter 
once a week until sacrifice. One, seven 
and 50 d after TM or vehicle treatment 
transgenic animals were sacrificed by 
CO
2
 asphyxiation followed by cervical 
dislocation. Blood was collected by car-
diac puncture and serum was isolated 
by centrifugation. Serum samples were 
stored at -20°C until use for hormone 
analysis. Organs (liver, brain, kidney, 
testes, epididymides, seminal vesicles, 
anterior and ventral prostates) were fixed 
in Bouin’s fixative for 6 h or snap-frozen 
in liquid nitrogen immediately after 
removal and stored at -80°C until further 
processing.
Figure 6. Immunohistochemical study 
of Ar expression in testes of iArKO and 
control mice treated with vehicle (V) or 
tamoxifen (tM) and evaluated seven and 
50 d after treatment. Animals were treated 
as explained in Figure 5 and Ar expression 
was evaluated on day 61 and day 104 (as 
indicated on the left side of the concerning 
parts). At least five animals were studied 
for each experimental group. Again the 
intensity of Ar staining was comparable in 
control mice treated with V or tM (A and 
B respectively) and iArKO animals treated 
with V (C). Ar staining was markedly dimin-
ished in iArKO mice treated with tM (D). In 
the latter animals virtually no Ar staining 
was observed in LCs, ptMs and testicular ar-
terioles. Ar staining could be detected in a 
number of SCs (white arrowheads) whereas 
others were negative (black arrowheads). 
Scale bar = 100 μm.
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GTT GAT ACC-3' (reverse primer). The floxed AR and the AR 
with an excised exon 2 could be recognized by a 952 bp and a 404 
bp band respectively. Effective excision of exon 2 was also studied 
on genomic DNA extracted from testis, epididymis, kidney and 
brain.
RNA extraction and quantitative RT-PCR. RNA was pre-
pared from testes derived from iARKO and control mice, treated 
with TM or vehicle, on day one, seven and 50 after the final 
injection. Testes were weighed and homogenized in a Dounce 
PCR genotyping. The genotype of iARKO and control ani-
mals was determined by PCR on genomic DNA extracted from 
tail tips. The presence of the Cre transgene was probed by use 
of the primer pair: 5'-GCG ATT ATC TTC TAT ATC TTC 
AGG-3' (forward primer) and 5'-GCC AAT ATG GAT TAA 
CAT TCT CCC-3' (reverse primer), revealing the presence or 
absence of a 380 bp band. The floxed AR allele was detected 
by use of the primer pair: 5'-AGC CTG TAT ACT CAG TTG 
GGG-3' (forward primer) and 5'-AAT GCA TCA CAT TAA 
Figure 7. evaluation of endocrine parameters in iArKO and control mice one day after the final injection with vehicle (V) or tamoxifen (tM). Serum 
levels of FSH, LH and testosterone and intratesticular levels of testosterone were measured in control and iArKO mice treated for five days with V or 
tM (n = 4–10). Measurements were performed on day 55, one day after the final injection. Assays were performed as described in the Methods section. 
testosterone levels in serum (C and e) and testes (D and F) were measured under basal conditions (C and D; [t]basal) and 2 h after stimulation with hCG 
(e and F; [t]stim). Values represent the mean ± SeM. Statistical analysis was performed as described in Figure 2. Values that differ significantly (p ≤ 0.05) 
are indicated by different lowercase letters (a–c).
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Histological evaluation and measurement of tubular diam-
eters. Testes derived from iARKO and control mice treated 
with vehicle or TM were immersion fixed in Bouin’s fluid for 6 
h at room temperature before being transferred into 70% etha-
nol until further processing. Fixed tissues were processed for 
12 h in an automated Shandon CitadelTM 1,000 tissue proces-
sor (Nijmegem, The Netherlands) and embedded in paraffin 
wax (Paraplast plus Tissue embedding medium; McCormick 
Scientific). Five-micrometer sections were cut, floated onto 
Superfrost® Plus slides (Menzel-Gläser, Thermo Scientific) and 
dried at 37°C overnight before being used for (immuno)histo-
chemistry as described below.
Immunohistochemical detection of AR protein was per-
formed on dewaxed and rehydrated sections. Heat-induced anti-
gen retrieval was performed for 10 min in 0.01 M citrate acid 
buffer (pH 6.0) using a pressure cooker. Thereafter slides were 





 (VWR International) in methanol for 30 min at 
room temperature. Between each of the following steps two washes 
(5 min) were performed using Tris [(Hydroxymethyl)methyl-
amine-buffered saline (TBS; 0.05 M Tris at pH 7.4 and 0.9% 
(wt/vol) saline)]. Sections were blocked with TBS contain-
ing 5% bovine serum albumin (wt/vol; Sigma-Aldrich) and 
normal goat serum (1/4 dilution; Dako) at room temperature 
before incubation overnight at 4°C with a rabbit anti-AR anti-
serum (1/750 in blocking buffer; sc-816 lot D3010 from Santa 
Cruz Biotechnology). Negative control samples were incubated 
overnight with blocking buffer without primary antibody. 
Thereafter, the sections were incubated with Envision + System-
HRP labeled Polymer Anti-Rabbit (K4003 from Dako) for 45 
min at room temperature. Bound antibodies were visualized by 
color development with 3,3'-diaminobenzidine tetrahydrochlo-
ride chromogenic substrate (K3468, Liquid DAB+ kit, Dako), 
monitored microscopically. Subsequently, sections were washed 
in tap water, counterstained with Haematoxylin Gill3 (Prosan 
homogenizer (Kontes Co.) and RNA was isolated with the 
RNeasy® Mini kit (Qiagen) according to the manufacturer’s 
instructions, encompassing an on-column deoxyribonuclease I 
(DNase I) treatment. Luciferase mRNA (10 ng; Promega) was 
added to the whole testis sample at the start of the RNA extrac-
tion procedure to control for the efficiency of RNA extraction, 
RNA degradation and the reverse transcription step and to allow 
specific mRNA levels to be expressed per testis.53
cDNA was synthesized from 1 μg RNA using Superscript II 
RT, RNaseOUT®TM and random hexamer primers (Invitrogen 
Life Technologies, Inc.) according to the manufacturer’s protocol. 
For quantification of gene expression, the 7500 Fast Real-Time 
PCR system (Applied Biosystems) was used running the ‘Fast 
RT-PCR’ protocol (2 min at 50°C, 2 min at 95°C and 40 cycles 
of 3 sec at 95°C and 30 sec at 60°C). For the quantification of AR, 
Spinlw1 (serine protease inhibitor-like, with Kunitz and WAP 
domains 1; formerly known as Eppin), StAR (steroidogenic acute 
regulatory protein), Cyp17a1 (steroid 17-α-hydroxylase/17,20-
lyase) and luciferase transcripts by quantitative real-time PCR 
(qPCR), each 10 μl qPCR reaction mix contained 1x Platinum® 
SYBR® Green qPCR SuperMix-UDG (Invitrogen), 150 nM of 
each primer and 0.05 μM ROX reference Dye (Invitrogen). For 
the AR an assay was designed that specifically recognizes tran-
scripts containing exon 2. The uniqueness of the amplified bands 
was verified by performing melting curves after the real-time 
PCR amplifications. For the Rhox5 qPCR assay, each 10 μl qPCR 
contained 1x TaqMan® Universal PCR Master Mix (Applied 
Biosystems), 1 μM of each primer and 4 μM probe. All samples 
were run in triplicate. The quantity of target mRNA was normal-
ized to an external luciferase mRNA standard, added before RNA 
extraction as described above. For comparison of transcript lev-
els, values were expressed relative to the average value of iARKO 
animals treated with vehicle (arbitrarily assigned a value of 100). 
Sequences of primers and probes are described in Table 3.
Table 3. Oligonucleotide primers and probes used for qpCr




Androgen receptor Ar NM_013476
Fw: 5'-GAC AtG CGt ttG GAC AGt ACC A-3'
rv: 5'-tGA CAG CCA GAA GCt tCA tCt C-3'
reproductive homeobox 5 Rhox5 NM_008818
Fw: 5'-tCA tCA ttG AtC CtA ttC AGG GtA tG-3'
rv: 5'-CtC tCC AGC CtG GAA GAA AGC-3'
probe: 5'-6-FAM-CtC GGA AGA ACA GCA tGA tGt GAA AGC A-tAMrA-3'
Serine protease inhibitor-like, with 
Kunitz and WAp domains 1 (eppin)
Spinlw1 NM_029325
Fw: 5'-GCt tCt GCt CCA AGC tCt GtG-3'
rv: 5'-ttG CAG tGC tCA AAG tGC tCt C-3'
Steroidogenic acute regulatory protein StAR NM_011485
Fw: 5'-CCG GAG CAG AGt GGt GtC A-3'
rv: 5'-CAG tGG AtG AAG CAC CAt GC-3'
Steroid 17-α-hydroxylase/17,20-lyase Cyp17a1 NM_007809
Fw: 5'-GGG CAC tGC AtC ACG AtA AA-3'




Fw: 5'-tCG AAG tAt tCC GCG tAC GtG-3'
rv: 5'-GCC CtG Gtt CCt GGA ACA A-3'
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-80°C. The pulverized testes were homogenized in 2 ml PBS 
(at 4°C) and were extracted twice with 4 ml of cyclohexane/
ethylacetate (50/50 vol/vol; VWR International). Each time 
the mixture was shaken for 30 min and centrifuged at 1,200x g 
for 10 min at room temperature. The two organic phases from 
the extraction steps were pooled and were evaporated to dry-
ness in a vacuum centrifuge (SAVANT SPD111V SpeedVac 
Concentration; Thermo Scientific). The final residue was dis-
solved in 200 μl charcoal stripped human serum. Serum LH 
levels were measured via an immunofluorometric assay (IFMA/
Delfia) at the University of Turku, Institute of Biomedicine, 
Department of Physiology.54,55
Statistical analysis. Comparison of body weights, organ 
weights, qPCR data, measurement of tubular diameters and 
hormone levels for iARKO and control animals treated with 
vehicle or TM at each age was made by ANOVA supplemented 
with a Fisher multiple comparison test using NCSS2000 soft-
ware (NCSS Statistical Analysis and Data Analysis Software). A 
p-value ≤ 0.05 was considered statistically significant.
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nv), dehydrated and mounted with DePex (VWR international). 
Images were captured using a Leica DMR microscope with a 
Sony DXC-9100P camera.
For morphological evaluation, 5 μm paraffin sections were 
prepared as described above. Subsequently, tissue sections were 
dewaxed, rehydrated and stained with Haematoxylin Gill3 
(Prosan nv) and eosin (71304E; Richard-Allan Scientific®) for 
2 min and 30 sec respectively. Finally, sections were dehydrated 
and mounted with DePex (VWR international).
Tubular diameters were measured at 20x magnification using 
an Axioplan 2 microscope (Carl Zeiss) and AxioVision Release 
4.6 software (Carl Zeiss). Three non-overlapping fields contain-
ing round or nearly round tubular sections were measured for 
each animal analyzed (at least three animals for each treatment 
group at all different ages). An equivalent tubular diameter was 
calculated as the average of two perpendicular measurements of 
each tubule for further analysis.
Measurements of LH, FSH and testosterone. Serum FSH 
levels were measured via a double-antibody RIA using reagents 
supplied by Dr. A.F. Parlow (Harbor-University of California-Los 
Angeles) and the National Institute of Diabetes and Digestive 
and Kidney Diseases, National Hormone and Peptide Program. 
The standard preparation used was mFSH, RP (lot AFP5308D), 
the tracer was prepared from rFSH IOD (lot AFP5178B) and the 
antiserum was rabbit anti-rFSH-S-11 A.S. (lot AFPC0972881). 
Testosterone was measured both under basal conditions and 
after stimulation with human Chorionic Gonadotropin (hCG; 
Pregnyl, Organon) in serum samples and in testicular extracts 
using the Testo-RIA-CT kit (Bio-Source International; detection 
limit, 0.05 ng/ml). Stimulated testosterone levels were obtained 
from animals treated with hCG (0.4 IU hCG/g body weight) 2 
h before sacrifice. Testicular extracts were obtained from testes 
snap-frozen in liquid nitrogen immediately after sacrifice of the 
animals and stored at -80°C until further processing. Collected 
testes were weighed and pulverized with a mortar cooled to 
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